



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

Patient Organisation Agreement

This Patient Organisation Agreement has been drawn up and entered into as of 11 December 2022 by and between

CSL Behring AB, Box 712, 182 17 Danderyd, SWEDEN, Reg. no. 556530-1974

and

HAE Scandinavia Strandkærvej 30, 1. 8700 Horsens Denmark, 31981670, info@haescan.org

1. Background

HAE Scandinavia focuses to improve quality of life and to support patients and their care-givers in Denmark, Sweden and Norway. The organization is working to establish a stronger collaboration between different stakeholders within the HAE field to enable optimal treatment and management of HAE patients and to raise awareness of the disease. CSL Behring operates in the HAE field by improving treatment for patients. There is a common interest in improving HAE treatment and care and to drive advocacy for improved patient access to treatment and care.

2. Collaboration project

Children's book – DK/NO/SE

CSL Behring will support the production of a children's book in Danish, Norwegian and Swedish language, based on the book "The rare boy and the talkative little balloon".

Support: DKK 33 000. This covers 30% of the total costs for this production.

Regional patient meetings in Denmark, Norway and Sweden

CSL Behring will support 3 regional patient meetings in Denmark (Horsens, Odense, and Copenhagen), 2 in Sweden (Stockholm and Malmø), and 2 in Norway (Oslo and Ålesund) held during 2022.

Support: DKK 80 000. This covers 30% of the total costs for these meetings.

HAE regional patient meeting, December 10th 2022, Bergen

CSL Behring will support a meeting for HAE patients and their families being held in collaboration with the dermatology department on Haukeland University Hospital. Aim of the meeting is to inform about the patient organization, provide disease information to improve everyday life for these patients as well as to inform how to best prepare children and youngsters for a life with prophylactic or acute treatment.

Total support: 7 000 NOK=DKK 5010.

Honorar to lecturer spesialsykepleier Siri Grønhaug, Sjeldne Diagnoser, OUS

Rikshospitalet: NOK 2 000

Overnatting: NOK 1 100

Konferansepakke: NOK 630

Fly t/r: NOK 2 500

Andre reiseutgifter: NOK 800

3. Finances

- 3.1 CSL Behring AB has undertaken to finance the listed projects in p2 with DKK 118 010. Payment shall be made against separate invoice. The invoice shall be sent to DanderydPayables@cslbehring.com

State Therese Feinberg as reference on the invoice.

4. Transparency

- 4.1 Both Parties consent to the contents of this Agreement being shared with a third party.
- 4.2 Both parties consent to this agreement or a summary thereof being published on the company website and reported to ENLI in accordance with § 3 of the Patient Organizations Code regulated by the Ethical Committee for the Pharmaceutical Industry, ENLI.

5. Consultation, evaluation

- 5.1 HAE Scandinavia has appointed Henrik Balle Boysen as their contact person in matters concerning this Agreement.
- 5.2 CSL Behring AB has appointed Tove Andersson as their contact person in matters concerning this Agreement.
- 5.3 After completion of the project, the Parties shall jointly evaluate the projects listed in p2 and their collaboration in relation to these projects.

6. Agreement period and early termination

- 6.1 This Agreement is valid from 12/12/2022 until 30/6/2023
- 6.2 If either party fails to fulfil their obligations pursuant to this Agreement and adjustments have not been made within thirty (30) days of the party being requested in writing to do so, the other party will be entitled to terminate the Agreement immediately.

7. Ethical rules and law

- 7.1 Ethical rules and national law apply to this agreement. HAE Scandinavia warrants that it will only use the funds received in accordance with national law and the Pharmaceutical Industry's Code of Ethics.
- 7.2 HAE Scandinavia may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval. HAE Scandinavia shall submit all proposed materials mentioning CSL Behring, or referring to CSL Behring's products, or the co-operation under this agreement, to CSL Behring for written approval prior to publication or use.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden


8. Disputes


If a dispute should arise in conjunction with this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days of the initial request for negotiation, the dispute shall be resolved in a Swedish Court.


9. E-signature

The Agreement may be executed by means of wet ink signatures or by using electronic signatures. If the Agreement is signed using electronic signatures, in making proof of this Agreement, an electronic copy of the Agreement will suffice. The Parties undertake not to dispute the validity of the Agreement based on the signatures being electronic.

This Agreement has been drawn up and signed in two (2) identical originals, of which each party has received an original.

Place and Date: Danderyd 12.12.22
CSL Behring AB:
DocuSigned by:

A2BDF6F9C5A5498.....
Name and title:
Tove Andersson
Digital Marketing and Patient Advocacy
Lead

Place and Date: Horsens, 19.12.22
HAE Scandinavia:
DocuSigned by:

8238B2D4A9F84C0.....
Name and title:
Henrik Balle Boysen
President HAE Scandinavia

Place and Date: Danderyd Dec 12 2022
CSL Behring AB:
DocuSigned by:

3BBB2BD230484A1.....
Name and title:
Martin Tenlén
General Manager